< Back to search
Filter
1

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

for
Prostatic Neoplasms, Castration-Resistant
Location: Quebec, Mineola NY, The Bronx NY, New York NY,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT07225946

Phase3, Recruiting

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

for
Prostate Cancer
Location: New York NY, Brooklyn NY
Sponsor: Weill Medical College of Cornell University

Sex: Male

Age: 18 - 70+

Code: NCT04886986

Phase1, Recruiting

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

for
Metastatic Prostate Cancer, Prostate Cancer
Location: San Francisco CA
Sponsor: University of California, San Francisco

Sex: Male

Age: 18+

Code: NCT07145177

Phase1, Recruiting

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

for
Metastatic Castration-Resistant Prostate Adenocarcinoma,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: Male

Age: 18+

Code: NCT07219147

Phase1, Recruiting

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

for
Prostate Cancer
Location: New York NY, Brooklyn NY
Sponsor: Weill Medical College of Cornell University

Sex: Male

Age: 18+

Code: NCT04946370

Phase1, Phase2, Recruiting

Interested in new metastatic castration-resistant prostate cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

for
Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma,
Location: Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: Male

Age: 18+

Code: NCT04704505

Phase2, Recruiting

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

for
Prostate Cancer
Location: Durham NC, Ann Arbor MI, Madison WI, San Francisco CA
Sponsor: Duke University

Sex: Male

Age: 18+

Code: NCT07050433

Recruiting

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

for
Castration-Resistant Prostate Carcinoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: Male

Age: 18+

Code: NCT06039371

Phase2, Recruiting

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

for
Castration-Resistant Prostate Carcinoma,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: Male

Age: 18+

Code: NCT05805371

Phase1, Recruiting

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

for
Castration Resistant Metastatic Prostate Cancer
Location: Boston MA, Baltimore MD, Minneapolis MN, Omaha NE,
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: Male

Age: 18 - 70+

Code: NCT04363164

Phase2, Recruiting
New

External Beam and Radioligand Radiotherapy for mCRPC

for
Prostate Cancer Metastatic Castration-Resistant
Location: Montreal
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Sex: Male

Age: 0+

Code: NCT07354594

Phase2, Recruiting

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

for
Metastatic Castration-Resistant Prostate Carcinoma,
Location: Seattle WA, San Francisco CA
Sponsor: University of Washington

Sex: Male

Age: 18+

Code: NCT06526299

Phase2, Recruiting

Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

for
Oligoprogressive, Castration-Resistant Prostate Cancer
Location: Toronto
Sponsor: Sunnybrook Health Sciences Centre

Sex: Male

Age: 18+

Code: NCT04838899

Recruiting

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

for
PSMA PET-Positive Castration-Resistant Prostate Cancer
Location: Boston MA, New York NY, Durham NC, Cleveland OH,
Sponsor: Convergent Therapeutics

Sex: Male

Age: 18+

Code: NCT06549465

Phase2, Recruiting

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

for
Castration Resistant Prostate Cancer,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: Male

Age: 18+

Code: NCT05919329

Recruiting

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

for
Metastatic Castration-Resistant Prostate Carcinoma,
Location: Commack NY, Uniondale NY, Harrison NY, The Bronx NY,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male

Age: 18+

Code: NCT07200830

Phase3, Recruiting

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

for
Esophageal Squamous Cell Carcinoma,
Location: Lake Success NY, Fairfax VA, Sarasota FL, Detroit MI,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT07503808

Phase1, Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

for
Castration-Resistant Prostatic Cancer, Metastasis
Location: Sherbrooke, New York NY, Montreal, Washington D.C. DC,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06863272

Phase1, Phase2, Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

for
Progressive Metastatic Castrate Resistant Prostate Cancer
Location: Halifax, Boston MA, Durham NC, Cleveland OH, Atlanta GA,
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18+

Code: NCT07206056

Phase1, Phase2, Recruiting

Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Location: Quebec
Sponsor: Jean-Mathieu Beauregard

Sex: Male

Age: 18+

Code: NCT06943495

Phase1, Recruiting